Literature DB >> 30631556

"Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer": is there a substantial difference or not?

Alessia Spagnuolo1, Cesare Gridelli1.   

Abstract

Entities:  

Year:  2018        PMID： 30631556      PMCID： PMC6297540          DOI： 10.21037/jtd.2018.09.83

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  5 in total

Review 1.  A Review of T-Cell Related Therapy for Osteosarcoma.

Authors:  Kazushige Yoshida; Masanori Okamoto; Kaoru Aoki; Jun Takahashi; Naoto Saito
Journal:  Int J Mol Sci       Date:  2020-07-10       Impact factor: 5.923

Review 2.  Immune checkpoint inhibitors in lymphoma: challenges and opportunities.

Authors:  Haris Hatic; Devi Sampat; Gaurav Goyal
Journal:  Ann Transl Med       Date:  2021-06

3.  Complete response with anti-PD-L1 antibody following progression on anti-PD-1 antibody in advanced non-small cell lung cancer.

Authors:  Navdeep Singh; Nagashree Seetharamu
Journal:  BMJ Case Rep       Date:  2020-08-24

4.  Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model.

Authors:  Pravin T P Kaumaya; Linlin Guo; Jay Overholser; Manuel L Penichet; Tanios Bekaii-Saab
Journal:  Oncoimmunology       Date:  2020-10-01       Impact factor: 8.110

Review 5.  Therapeutic and Systemic Adverse Events of Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 axis for Clinical Management of NSCLC.

Authors:  Jing Chen; Yaser Alduais; Baoan Chen
Journal:  Cell Transplant       Date:  2021 Jan-Dec       Impact factor: 4.064
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.